May 6th 2024
Probiotic supplementation was associated with the reduction of conjugated bile acids, cholesterol levels, and the oxidation of LDL cholesterol.
Omega-3 Pharmaceuticals Go Head to Head
January 7th 2011Privately held specialty pharmaceuticals firm Omthera Pharmaceuticals (Bedminster, NJ) has announced the results of tests it performed comparing its Epanova omega-3 fatty acid drug for high triglycerides to leading omega-3 drug Lovaza. The company says results show that Epanova was significantly more bioavailable than Lovaza.
Natto Pharma Secures EU Patents for Vitamin K and Heart Health
December 16th 2010Vitamin K specialist Natto Pharma (Lysaker, Norway) announced on Wednesday that the company has successfully defended two EU patents for vitamin K1 and K2 in heart health. The first patent claims vitamin K's use for decalcification of blood vessels and the second claims its use in preventing age-related stiffening of arteries, the company reported.
Hypertension: Sodium: There’s More to the Story
December 1st 2010With much attention today on sodium reduction and hypertension, a fact often overlooked is that sodium is only one piece of the hypertension puzzle. Other nutrients can come into play. Potassium, for instance, which plays a role in water balance and blood flow, can blunt the effects of sodium on blood pressure.
GOED Responds to Poor Results of Omega-3 Heart Health Study
September 23rd 2010A study published last Sunday in the New England Journal of Medicine is receiving ample response from omega-3 industry organizations. Using a population cohort of nearly 5,000 people who supplemented with omega-3-enriched margerines for 40 months, researchers behind the study concluded that 'Low doses of omega-3 fatty acids did not significantly reduce the rates of cardiovascular end points.' This was determined to be the case with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA).